Evidence map›Paper›PMID 34986195›Full record

ArticlePloS one2022

Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol™) in adults residing in Lukanga Swamps of Zambia.

Harriet Ng Ombe, Michelo Simuyandi, John Mwaba, Charlie Chaluma Luchen, Peter Alabi, Obvious Nchimunya Chilyabanyama, Cynthia Mubanga, Luiza Miyanda Hatyoka, Mutinta Muchimba, Samuel Bosomprah and 3 more

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Plant-based edible vaccines: Can cholera be the case study in Africa?Journal, genetic engineering & biotechnology · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Harriet Ng OmbeCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.ORCID 0000-0002-3601-0660
Michelo SimuyandiCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.
John MwabaCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.
Charlie Chaluma LuchenCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.
Peter AlabiCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.
Obvious Nchimunya ChilyabanyamaCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.
Cynthia MubangaCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.
Luiza Miyanda HatyokaCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.
Mutinta MuchimbaCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.
Samuel BosomprahCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.
Roma ChilengiCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.ORCID 0000-0003-0221-9527
Geoffrey KwendaDepartment of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka, Zambia.
Caroline Cleopatra ChisengaCenter for Infectious Disease Research in Zambia, Lusaka, Zambia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn cholera endemic areas, the periodicity of cholera outbreaks remains unpredictable, making it difficult to organize preventive efforts. Lack of data on duration of protection conferred by oral cholera vaccines further makes it difficult to determine when to deploy preemptive vaccination. We report on the immunogenicity and waning of immunity to Shanchol™ in Lukanga Swamps.

methodsWe enrolled a cohort of 223 participants aged between 18 and 65 years old from whom serum samples were collected at baseline, day 28 before administration of the second dose, and consecutively at 6, 12, 24, 30, 36, and 48 months. Vibriocidal antibody titres were measured and expressed as geometric mean titres. Box plots and 95% CI were computed at each visit for both Inaba and Ogawa. Seroconversion was defined as a four fold or greater increase in antibody titres compared to baseline titres.

resultsOverall, seroconversion against V. cholerae Inaba and Ogawa after 1st dose was 35/134 (26%) and 34/134 (25%) respectively. We observed a statistical difference in seroconversion between the two subgroups of baseline titres (low <80 and high ≥80) for both Inaba (p = 0.02) and Ogawa (p<0.0001). From a baseline of 13.58, anti-Ogawa GMT increased to 21.95 after the first dose, but rapidly waned to 14.52, 13.13, and 12.78 at months 6, 12 and 24 respectively, and then increased to 13.21, 18.67 and 23.65 at months 30, 36 and 48 respectively. A similar trend was observed for anti-Inaba GMT across the same time points.

conclusionWe found that Shanchol™ was immunogenic in our study population and that vibriocidal antibodies may not be a good marker for long-term immunity. The observed rise in titres after 36 months suggests natural exposure, and this may be a critical time window opening for natural transmission in an endemic areas. We recommend re-vaccination at this time point in high risk areas.

Indexed as

Administration, OralAdolescentAdultAntibodies, BacterialCholeraCholera VaccinesEndemic DiseasesFemaleHumansMaleMiddle AgedPeriodicityPopulation SurveillanceSeroconversionVibrio choleraeWetlandsAntibodies, BacterialCholera Vaccines

Identifiers

PMID34986195
PMCPMC8730422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.